Mechanisms of Jak/STAT signaling in immunity and disease

Journal of Immunology

Volumn 194, Issue 1, 2015, Pages 21-27

  Villarino, Alejandro V ^a   Kanno, Yuka ^a   Ferdinand, John R ^a   O'Shea, John J ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; JANUS KINASE; STAT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; CYTOKINE; DNA BINDING PROTEIN;

CELL COMMUNICATION; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SPECIFICITY; GENE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DETERMINATION; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAT GENE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION;

CYTOKINES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; JANUS KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84919684042     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401867     Document Type: Review

References (79)

1. Wang, Y., and D. E. Levy. 2012. Comparative evolutionary genomics of the STAT family of transcription factors. JAK-STAT 1: 23-33.
2. Stark, G. R., and J. E. Darnell, Jr. 2012. The JAK-STAT pathway at twenty. Immunity 36: 503-514.
3. Brooks, A. J., W. Dai, M. L. O'Mara, D. Abankwa, Y. Chhabra, R. A. Pelekanos, O. Gardon, K. A. Tunny, K. M. Blucher, C. J. Morton, et al. 2014. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344: 1249783.
4. O'Shea, J. J., and P. J. Murray. 2008. Cytokine signaling modules in inflammatory responses. Immunity 28: 477-487.
5. Cho, S. S., C. M. Bacon, C. Sudarshan, R. C. Rees, D. Finbloom, R. Pine, and J. J. O'Shea. 1996. Activation of STAT4 by IL-12 and IFN-Alpha: Evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J. Immunol. 157: 4781-4789.
6. Villarino, A., L. Hibbert, L. Lieberman, E. Wilson, T. Mak, H. Yoshida, R. A. Kastelein, C. Saris, and C. A. Hunter. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19: 645-655.
7. Seidel, H. M., L. H. Milocco, P. Lamb, J. E. Darnell, Jr., R. B. Stein, and J. Rosen. 1995. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA 92: 3041-3045.
8. O'Shea, J. J., R. Lahesmaa, G. Vahedi, A. Laurence, and Y. Kanno. 2011. Genomic views of STAT function in CD4+ T helper cell differentiation. Nat. Rev. Immunol. 11: 239-250.
9. Robertson, G., M. Hirst, M. Bainbridge, M. Bilenky, Y. Zhao, T. Zeng, G. Euskirchen, B. Bernier, R. Varhol, A. Delaney, et al. 2007. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods 4: 651-657.
10. Kanno, Y., G. Vahedi, K. Hirahara, K. Singleton, and J. J. O'Shea. 2012. Transcriptional and epigenetic control of T helper cell specification: Molecular mechanisms underlying commitment and plasticity. Annu. Rev. Immunol. 30: 707-731.
11. Langlais, D., C. Couture, A. Balsalobre, and J. Drouin. 2012. The Stat3/GR interaction code: Predictive value of direct/indirect DNA recruitment for transcription outcome. Mol. Cell 47: 38-49.
12. Wei, L., G. Vahedi, H.-W. Sun, W. T. Watford, H. Takatori, H. L. Ramos, H. Takahashi, J. Liang, G. Gutierrez-Cruz, C. Zang, et al. 2010. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity 32: 840-851.
13. Zhu, B. M., K. Kang, J. H. Yu, W. Chen, H. E. Smith, D. Lee, H. W. Sun, L. Wei, and L. Hennighausen. 2012. Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genes. Nucleic Acids Res. 40: 4461-4472.
14. Kang, K., G. W. Robinson, and L. Hennighausen. 2013. Comprehensive metaanalysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics 14: 4.
15. Decker, T., P. Kovarik, and A. Meinke. 1997. GAS elements: A few nucleotides with a major impact on cytokine-induced gene expression. J. Interferon Cytokine Res. 17: 121-134.
16. Walker, S. R., E. A. Nelson, J. E. Yeh, L. Pinello, G. C. Yuan, and D. A. Frank. 2013. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol. Cell. Biol. 33: 2879-2890.
17. Wan, C.-K., J. Oh, P. Li, E. E. West, E. A. Wong, A. B. Andraski, R. Spolski, Z.-X. Yu, J. He, B. L. Kelsall, and W. J. Leonard. 2013. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 38: 514-527.
18. Yang, X.-P., K. Ghoreschi, S. M. Steward-Tharp, J. Rodriguez-Canales, J. Zhu, J. R. Grainger, K. Hirahara, H.-W. Sun, L. Wei, G. Vahedi, et al. 2011. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12: 247-254.
19. Bezbradica, J. S., R. K. Rosenstein, R. A. DeMarco, I. Brodsky, and R. Medzhitov. 2014. A role for the ITAM signaling module in specifying cytokine-receptor functions. Nat. Immunol. 15: 333-342.
20. Nagashima, H., Y. Okuyama, A. Asao, T. Kawabe, S. Yamaki, H. Nakano, M. Croft, N. Ishii, and T. So. 2014. The adaptor TRAF5 limits the differentiation of inflammatory CD4(+) T cells by antagonizing signaling via the receptor for IL-6. Nat. Immunol. 15: 449-456.
21. Zhou, V. W., A. Goren, and B. E. Bernstein. 2011. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 12: 7-18.
22. Wilson, C. B., E. Rowell, and M. Sekimata. 2009. Epigenetic control of T-helpercell differentiation. Nat. Rev. Immunol. 9: 91-105.
23. Mandal, M., S. E. Powers, M. Maienschein-Cline, E. T. Bartom, K. M. Hamel, B. L. Kee, A. R. Dinner, and M. R. Clark. 2011. Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat. Immunol. 12: 1212-1220.
24. Chen, X., H. Xu, P. Yuan, F. Fang, M. Huss, V. B. Vega, E. Wong, Y. L. Orlov, W. Zhang, J. Jiang, et al. 2008. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133: 1106-1117.
25. Ciofani, M., A. Madar, C. Galan, M. Sellars, K. Mace, F. Pauli, A. Agarwal, W. Huang, C. N. Parkurst, M. Muratet, et al. 2012. A validated regulatory network for Th17 cell specification. Cell 151: 289-303.
26. Farlik, M., B. Reutterer, C. Schindler, F. Greten, C. Vogl, M. Muller, and T. Decker. 2010. Nonconventional initiation complex assembly by STAT and NF-kappaB transcription factors regulates nitric oxide synthase expression. Immunity 33: 25-34.
27. Korzus, E., J. Torchia, D. W. Rose, L. Xu, R. Kurokawa, E. M. McInerney, T. M. Mullen, C. K. Glass, and M. G. Rosenfeld. 1998. Transcription factorspecific requirements for coactivators and their acetyltransferase functions. Science 279: 703-707.
28. Qiao, Y., E. G. Giannopoulou, C. H. Chan, S.-H. Park, S. Gong, J. Chen, X. Hu, O. Elemento, and L. B. Ivashkiv. 2013. Synergistic activation of inflammatory cytokine genes by interferon-g-induced chromatin remodeling and toll-like receptor signaling. Immunity 39: 454-469.
29. Kwon, H., D. Thierry-Mieg, J. Thierry-Mieg, H. P. Kim, J. Oh, C. Tunyaplin, S. Carotta, C. E. Donovan, M. L. Goldman, P. Tailor, et al. 2009. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31: 941-952.
30. Natoli, G. 2010. Maintaining cell identity through global control of genomic organization. Immunity 33: 12-24.
31. Hnisz, D., B. J. Abraham, T. I. Lee, A. Lau, V. Saint-André, A. A. Sigova, H. A. Hoke, and R. A. Young. 2013. Super-enhancers in the control of cell identity and disease. Cell 155: 934-947.
32. Parker, S. C., M. L. Stitzel, D. L. Taylor, J. M. Orozco, M. R. Erdos, J. A. Akiyama, K. L. van Bueren, P. S. Chines, N. Narisu, B. L. Black, et al.; NISC Comparative Sequencing Program.; National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program Authors.; NISC Comparative Sequencing Program Authors. 2013. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc. Natl. Acad. Sci. USA 110: 17921-17926.
33. Vahedi, G., H. Takahashi, S. Nakayamada, H.-W. Sun, V. Sartorelli, Y. Kanno, and J. J. O'Shea. 2012. STATs shape the active enhancer landscape of T cell populations. Cell 151: 981-993.
34. Hu, G., Q. Tang, S. Sharma, F. Yu, T. M. Escobar, S. A. Muljo, J. Zhu, and K. Zhao. 2013. Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation. Nat. Immunol. 14: 1190-1198.
35. Kuchen, S., W. Resch, A. Yamane, N. Kuo, Z. Li, T. Chakraborty, L. Wei, A. Laurence, T. Yasuda, S. Peng, et al. 2010. Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 32: 828-839.
36. Collier, S. P., P. L. Collins, C. L. Williams, M. R. Boothby, and T. M. Aune. 2012. Cutting edge: Influence of Tmevpg1, a long intergenic noncoding RNA, on the expression of Ifng by Th1 cells. J. Immunol. 189: 2084-2088.
37. Gomez, J. A., O. L. Wapinski, Y. W. Yang, J. F. Bureau, S. Gopinath, D. M. Monack, H. Y. Chang, M. Brahic, and K. Kirkegaard. 2013. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferong locus. Cell 152: 743-754.
38. Kohanbash, G., and H. Okada. 2011. MicroRNAs and STAT interplay. Semin. Cancer Biol. 22: 70-75.
39. Wang, P., Y. Xue, Y. Han, L. Lin, C. Wu, S. Xu, Z. Jiang, J. Xu, Q. Liu, and X. Cao. 2014. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science 344: 310-313.
40. Collison, L. W., G. M. Delgoffe, C. S. Guy, K. M. Vignali, V. Chaturvedi, D. Fairweather, A. R. Satoskar, K. C. Garcia, C. A. Hunter, C. G. Drake, et al. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 13: 290-299.
41. Lin, J.-X., P. Li, D. Liu, H.-T. Jin, J. He, M. Ata Ur Rasheed, Y. Rochman, L. Wang, K. Cui, C. Liu, et al. 2012. Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36: 586-599.
42. Begitt, A., M. Droescher, T. Meyer, C. D. Schmid, M. Baker, F. Antunes, K.-P. Knobeloch, M. R. Owen, R. Naumann, T. Decker, and U. Vinkemeier. 2014. STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nat. Immunol. 15: 168-176.
43. Miyagi, T., M. P. Gil, X. Wang, J. Louten, W. M. Chu, and C. A. Biron. 2007. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J. Exp. Med. 204: 2383-2396.
44. Zhang, S., S. Fukuda, Y. Lee, G. Hangoc, S. Cooper, R. Spolski, W. J. Leonard, and H. E. Broxmeyer. 2000. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J. Exp. Med. 192: 719-728.
45. Gao, X., H. Wang, J. J. Yang, X. Liu, and Z.-R. Liu. 2012. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45: 598-609.
46. Chen, H., H. Sun, F. You, W. Sun, X. Zhou, L. Chen, J. Yang, Y. Wang, H. Tang, Y. Guan, et al. 2011. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 147: 436-446.
47. Bancerek, J., Z. C. Poss, I. Steinparzer, V. Sedlyarov, T. Pfaffenwimmer, I. Mikulic, L. Dölken, B. Strobl, M. Muller, D. J. Taatjes, and P. Kovarik. 2013. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 38: 250-262.
48. Decker, T., and P. Kovarik. 2000. Serine phosphorylation of STATs. Oncogene 19: 2628-2637.
49. Morinobu, A., M. Gadina, W. Strober, R. Visconti, A. Fornace, C. Montagna, G. M. Feldman, R. Nishikomori, and J. J. O'Shea. 2002. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc. Natl. Acad. Sci. USA 99: 12281-12286.
50. Shen, Y., K. Schlessinger, X. Zhu, E. Meffre, F. Quimby, D. E. Levy, and J. E. Darnell, Jr. 2004. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol. Cell. Biol. 24: 407-419.
51. Varinou, L., K. Ramsauer, M. Karaghiosoff, T. Kolbe, K. Pfeffer, M. Muller, and T. Decker. 2003. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 19: 793-802.
52. Friedbichler, K., M. A. Kerenyi, B. Kovacic, G. Li, A. Hoelbl, S. Yahiaoui, V. Sexl, E. W. Mullner, S. Fajmann, S. Cerny-Reiterer, et al. 2010. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 116: 1548-1558.
53. Meissner, T., E. Krause, I. Lödige, and U. Vinkemeier. 2004. Arginine methylation of STAT1: A reassessment. Cell 119: 587-589, discussion 589-590.
54. O'Shea, J. J., Y. Kanno, X. Chen, and D. E. Levy. 2005. Cell signaling. Stat acetylation-A key facet of cytokine signaling? Science 307: 217-218.
55. Kim, E., M. Kim, D.-H. Woo, Y. Shin, J. Shin, N. Chang, Y. T. Oh, H. Kim, J. Rheey, I. Nakano, et al. 2013. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stemlike cells. Cancer Cell 23: 839-852.
56. Yang, J., J. Huang, M. Dasgupta, N. Sears, M. Miyagi, B. Wang, M. R. Chance, X. Chen, Y. Du, Y. Wang, et al. 2010. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc. Natl. Acad. Sci. USA 107: 21499-21504.
57. Begitt, A., M. Droescher, K. P. Knobeloch, and U. Vinkemeier. 2011. SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNg. Blood 118: 1002-1007.
58. Van Nguyen, T., P. Angkasekwinai, H. Dou, F.-M. Lin, L.-S. Lu, J. Cheng, Y. E. Chin, C. Dong, and E. T. Yeh. 2012. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol. Cell 45: 210-221.
59. Meier, J. A., and A. C. Larner. 2014. Toward a new STATe: The role of STATs in mitochondrial function. Semin. Immunol. 26: 20-28.
60. Dawson, M. A., A. J. Bannister, B. Göttgens, S. D. Foster, T. Bartke, A. R. Green, and T. Kouzarides. 2009. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461: 819-822.
61. O'Shea, J. J., S. M. Holland, and L. M. Staudt. 2013. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368: 161-170.
62. Casanova, J. L., S. M. Holland, and L. D. Notarangelo. 2012. Inborn errors of human JAKs and STATs. Immunity 36: 515-528.
63. Noguchi, M., H. Yi, H. M. Rosenblatt, A. H. Filipovich, S. Adelstein, W. S. Modi, O. W. McBride, and W. J. Leonard. 1993. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73: 147-157.
64. Macchi, P., A. Villa, S. Giliani, M. G. Sacco, A. Frattini, F. Porta, A. G. Ugazio, J. A. Johnston, F. Candotti, J. J. O'Shea, et al. 1995. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377: 65-68.
65. Russell, S. M., N. Tayebi, H. Nakajima, M. C. Riedy, J. L. Roberts, M. J. Aman, T.-S. Migone, M. Noguchi, M. L. Markert, R. H. Buckley, et al. 1995. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270: 797-800.
66. Steward-Tharp, S. M., A. Laurence, Y. Kanno, A. Kotlyar, A. V. Villarino, G. Sciume, S. Kuchen, W. Resch, E. A. Wohlfert, K. Jiang, et al. 2014. A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Blood 123: 2978-2987.
67. Flanagan, S. E., E. Haapaniemi, M. A. Russell, R. Caswell, H. Lango Allen, E. De Franco, T. J. McDonald, H. Rajala, A. Ramelius, J. Barton, et al. 2014. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat. Genet. 46: 812-814.
68. Manolio, T. A. 2013. Bringing genome-wide association findings into clinical use. Nat. Rev. Genet. 14: 549-558.
69. Vercelli, D. 2008. Discovering susceptibility genes for asthma and allergy. Nat. Rev. Immunol. 8: 169-182.
70. Bromberg, J. 2002. Stat proteins and oncogenesis. J. Clin. Invest. 109: 1139-1142.
71. Yu, H., D. Pardoll, and R. Jove. 2009. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9: 798-809.
72. Levine, R. L., A. Pardanani, A. Tefferi, and D. G. Gilliland. 2007. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 7: 673-683.
73. Ungureanu, D., J. Wu, T. Pekkala, Y. Niranjan, C. Young, O. N. Jensen, C.-F. Xu, T. A. Neubert, R. C. Skoda, S. R. Hubbard, and O. Silvennoinen. 2011. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18: 971-976.
74. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat. Immunol. 10: 356-360.
75. Cosgrove, S. B., J. A.Wren, D. M. Cleaver, K. F.Walsh, S. I. Follis, V. I. King, J.-K. S. Tena, and M. R. Stegemann. 2013. A blinded, randomized, placebocontrolled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis. Vet. Dermatol. 24: 587- 597, e141-e142.
76. Sen, M., and J. R. Grandis. 2012. Nucleic acid-based approaches to STAT inhibition. JAK-STAT 1: 285-291.
77. Koo, M. Y., J. Park, J. M. Lim, S. Y. Joo, S.-P. Shin, H. B. Shim, J. Chung, D. Kang, H. A. Woo, and S. G. Rhee. 2014. Selective inhibition of the function of tyrosine-phosphorylated STAT3 with a phosphorylation site-specific intrabody. Proc. Natl. Acad. Sci. USA 111: 6269-6274.
78. Haapaniemi, E. M., M. Kaustio, H. L. M. Rajala, A. J. van Adrichem, L. Kainulainen, V. Glumoff, R. Doffinger, H. Kuusanmaki, T. Heiskanen-Kosma, L. Trotta, et al. 2014. Autoimmunity, hypogammaglobulinemia, lymphoproliferation and mycobacterial disease in patients with dominant activating mutations in STAT3. Blood. DOI: 10.1182/blood-2014-04-570101.
79. Milner, J. D., T. P. Vogel, L. Forbes, C. A. Ma, A. Stray-Pedersen, J. E. Niemela, J. J. Lyons, K. R. Engelhardt, Y. Zhang, N. Topcagic, et al. 2014. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-offunction mutations. Blood. DOI: 10.1182/blood-2014-09-602763.